People with neuromyelitis optica spectrum disorder (NMOSD) experience faster disability progression with fewer attacks than those with myelin oligodendrocyte…
Articles by Lindsey Shapiro, PhD
Nearly 1 in 5 people with neuromyelitis optica spectrum disorder (NMOSD) experience early neurological symptoms prior to their first…
AstraZeneca has announced filing a legal challenge to certain aspects of the U.S. Inflation Reduction Act (IRA), arguing…
Certain neurological symptoms of neuromyelitis optica spectrum disorder (NMOSD) occur at higher rates in patients who also have…
CCL2, a signaling protein that recruits immune cells to sites of injury, may play a key role in driving the…
Ultomiris (ravulizumab) has been approved by authorities in Japan to prevent relapses in adults with neuromyelitis optica spectrum…
The risk of neuromyelitis optica spectrum disorder (NMOSD) attacks following vaccination is low, and such attacks have not been…
A small subset of people with neuromyelitis optica spectrum disorder (NMOSD) do not accumulate significant functional disability in the…
SPHERES, a real-world registry for neuromyelitis optica spectrum disorder (NMOSD), is now collecting biological samples from consenting participants.
High-efficacy treatments for neuromyelitis optica spectrum disorder (NMOSD) are associated with significant reductions in hospitalizations, relapses, and MRI lesions…